Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Apixaban in Severe Renal Impairment

Trial Profile

Safety and Efficacy of Apixaban in Severe Renal Impairment

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary)
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Aug 2022 Planned End Date changed from 10 Jul 2019 to 24 Aug 2022.
    • 07 Jul 2019 Planned primary completion date changed from 10 May 2019 to 7 Jul 2019.
    • 22 Jan 2018 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top